Should You Buy Humacyte Inc (HUMA) Stock Tuesday Morning?

Humacyte Inc (HUMA) is higher by Tuesday morning, with the stock increasing 10.81% in pre-market trading to 4.1. HUMA's short-term technical score of 26 indicates that the stock has traded less bullishly over the last month than 74% of stocks on the market. In the Biotechnology industry, which ranks 132 out of 146 industries, HUMA ranks higher than 44% of stocks. Humacyte Inc has risen 13.15% over the past month, closing at $4.48 on August 15. During this period of time, the stock fell as low as $3.37 and as high as $4.74. HUMA has an average analyst recommendation of Strong Buy. The company has an average price target of $7.10.

HUMA has an Overall Score of 49. Find out what this means to you and get the rest of the rankings on HUMA!

See Full HUMA Report

Humacyte Inc has a Long-Term Technical rank of 47. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 53% of the market scoring higher. In the Biotechnology industry which is number 132 by this metric, HUMA ranks better than 132% of stocks.

Important Dates for Investors in HUMA:

-Humacyte Inc is set to release earnings on 2023-11-12. Over the last 12 months, the company has reported EPS of $-0.86. -We do not have a set dividend date for Humacyte Inc at this time. Click Here To Get The Full Report on Humacyte Inc (HUMA)